C

China National Accord Medicines Corp Ltd
SZSE:000028

Watchlist Manager
China National Accord Medicines Corp Ltd
SZSE:000028
Watchlist
Price: 25 CNY -0.75% Market Closed
Market Cap: ¥13.9B

China National Accord Medicines Corp Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China National Accord Medicines Corp Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
China National Accord Medicines Corp Ltd
SZSE:000028
Cash from Operating Activities
¥1.6B
CAGR 3-Years
-14%
CAGR 5-Years
2%
CAGR 10-Years
1%
Sinopharm Group Co Ltd
HKEX:1099
Cash from Operating Activities
¥18.4B
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
3%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Cash from Operating Activities
¥6.2B
CAGR 3-Years
9%
CAGR 5-Years
-2%
CAGR 10-Years
16%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Cash from Operating Activities
¥3.4B
CAGR 3-Years
-11%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
C
China National Medicines Corp Ltd
SSE:600511
Cash from Operating Activities
¥2B
CAGR 3-Years
-6%
CAGR 5-Years
9%
CAGR 10-Years
16%
Huadong Medicine Co Ltd
SZSE:000963
Cash from Operating Activities
¥3.9B
CAGR 3-Years
17%
CAGR 5-Years
5%
CAGR 10-Years
27%
No Stocks Found

China National Accord Medicines Corp Ltd
Glance View

Market Cap
13.9B CNY
Industry
Health Care

China National Accord Medicines Corp Ltd, nestled within the bustling healthcare landscape of China, operates at the heart of the pharmaceutical distribution and retail sectors. Established with the goal of ensuring that essential medicines and healthcare services are accessible to the vast Chinese population, the company has built an extensive distribution network. This network efficiently links manufacturers with hospitals, clinics, and pharmacies, making certain that a myriad of pharmaceutical products reach their intended destinations. By leveraging a combination of logistical prowess and vast geographical coverage, the company adeptly navigates the complexities of supply chain management, underscoring its role as a critical player in China's healthcare infrastructure. Beyond distribution, China National Accord Medicines also capitalizes on the booming retail pharmaceuticals market through its chain of pharmacies. These retail outlets serve as direct points of sale to consumers, offering both prescription and over-the-counter medications, alongside health consultation services. This dual focus on both wholesale distribution and retail outlets enables the company to capture value across the supply chain, from manufacturer to end-user. The strategic alignment of its operations streamlines efficiency and generates revenue, sustaining its growth amid a fiercely competitive and rapidly evolving market. Through this integrated approach, the company solidifies its position as a crucial conduit in the delivery of healthcare solutions across China.

Intrinsic Value
73.5 CNY
Undervaluation 66%
Intrinsic Value
Price ¥25
C

See Also

What is China National Accord Medicines Corp Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.6B CNY

Based on the financial report for Dec 31, 2025, China National Accord Medicines Corp Ltd's Cash from Operating Activities amounts to 1.6B CNY.

What is China National Accord Medicines Corp Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
1%

Over the last year, the Cash from Operating Activities growth was -50%. The average annual Cash from Operating Activities growth rates for China National Accord Medicines Corp Ltd have been -14% over the past three years , 2% over the past five years , and 1% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett